tiprankstipranks
Cue Biopharma Inc (CUE)
NASDAQ:CUE
US Market
CUE
Cue Biopharma
RESEARCH TOOLSreports
Want to see CUE full AI Analyst Report?

Cue Biopharma (CUE) Earnings Dates, Call Summary & Reports

662 Followers

Earnings Data

Report Date
Aug 18, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-1.69
Last Year’s EPS
-2.7
Same Quarter Last Year
Analyst Consensus
―
Based on 0 Analysts Ratings

Earnings Call Summary

Q2 2024
Earnings Call Date:Aug 19, 2024|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call presented several positive developments in clinical trials and strategic financial management, but also noted delays in trial launches and competitive market challenges.
Company Guidance
During Cue Biopharma's Q2 2024 earnings call, the executives provided guidance on several metrics and strategic priorities. They highlighted their focus on reducing capital requirements by achieving a cash burn reduction from $40 million to $30 million annually, extending their runway to mid-2025. The company is advancing its CUE-101 and CUE-102 oncology programs, with CUE-101 showing an objective response rate of 46% and a notable 12-month overall survival rate of 90% in a combination trial with pembrolizumab. Cue-401, in collaboration with ONO Pharmaceuticals, targets autoimmune diseases, with lead candidate selection anticipated in Q1 2025. Additionally, CUE-501 is being positioned for strategic partnering, aimed at addressing B-cell-mediated autoimmune diseases. The company's approach includes leveraging strategic partnerships to optimize resource allocation and bolster cash flow through milestone payments and potential co-development agreements.
CUE-101 and Pembrolizumab Combination Shows Promising Results
CUE-101 in combination with Pembrolizumab shows an objective response rate (ORR) of 46% in patients with CPS ≥ 1, compared to the historical ORR of 19% with Pembrolizumab alone. The 12-month overall survival (OS) is 90% with a median OS of 21.8 months.
Strong Performance in Low CPS Score Patients
Patients with low CPS scores (1 to 19) showed an ORR of 50% with CUE-101 and Pembrolizumab, significantly higher than the historical 15% with Pembrolizumab alone.
CUE-401 Autoimmune Program Progress
CUE-401, in collaboration with ONO Pharmaceuticals, shows promising data in generating regulatory T cells and is moving towards lead candidate selection in Q1 2025.
Financial Strategy and Extended Runway
Through strategic measures, the company's runway is extended to mid-2025 while reducing annual cash burn from $40 million to $30 million.

Cue Biopharma (CUE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

CUE Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 18, 2026
2026 (Q2)
-1.69 / -
-2.7―――
May 14, 2026
2026 (Q1)
- / -1.08
-5.178.82% (+4.02)――
Mar 16, 2026
2025 (Q4)
-2.70 / 0.30
-3.9107.69% (+4.20)――
Nov 12, 2025
2025 (Q3)
-2.80 / -2.10
-5.158.82% (+3.00)――
Aug 12, 2025
2025 (Q2)
-3.90 / -2.70
-655.00% (+3.30)――
May 12, 2025
2025 (Q1)
- / -0.17
-7.597.73% (+7.33)――
Mar 31, 2025
2024 (Q4)
-4.60 / -5.10
-7.532.00% (+2.40)――
Nov 14, 2024
2024 (Q3)
-5.47 / -5.10
-7.229.17% (+2.10)――
Aug 19, 2024
2024 (Q2)
-8.40 / -6.00
-8.731.03% (+2.70)―
May 09, 2024
2024 (Q1)
- / -
-0.29―――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CUE Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 14, 2026
$25.33$23.01-9.16%
Mar 16, 2026
$9.35$8.14-12.85%
Nov 12, 2025
$20.03$18.59-7.19%
Aug 12, 2025
$23.70$24.31+2.57%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cue Biopharma Inc (CUE) report earnings?
Cue Biopharma Inc (CUE) is schdueled to report earning on Aug 18, 2026, TBA (Confirmed).
    What is Cue Biopharma Inc (CUE) earnings time?
    Cue Biopharma Inc (CUE) earnings time is at Aug 18, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CUE EPS forecast?
          CUE EPS forecast for the fiscal quarter 2026 (Q2) is -1.69.